rel-N-(5-Bromopentyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide

Catalog No. :
ACCLAF462
CAS No. :
1217605-72-5
Molecular Formula :
C15H26BrN3O2S
Molecular Weight :
392.36

IUPAC Name:N-(5-bromopentyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide

rel-N-(5-Bromopentyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$281.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namerel-N-(5-Bromopentyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
IUPAC NameN-(5-bromopentyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
Molecular FormulaC15H26BrN3O2S
Molecular Weight392.36
SMILESO=C(NCCCCCBr)CCCC[C@H]1SC[C@@]([C@@]1([H])N2)([H])NC2=O
InChI KeyBBMKEQZLWUFNDA-YRGRVCCFSA-N
SynonymN-Biotinyl-5-bromopentylamine
CAS No.1217605-72-5
PubChem CID71433555

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACCLAF462 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGHJF702 route compound structure diagram
    ACGHJF70251874-27-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCLAF462 route product structure diagram
    ACCLAF4621217605-72-5
Inquiry

2. ACCLAF462 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGHJF702 route compound structure diagram
    ACGHJF70251874-27-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCLAF462 route product structure diagram
    ACCLAF4621217605-72-5
Inquiry

Comments (0)